Deciphera Pharmaceuticals Ownership | Who Owns Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals Ownership Summary
Deciphera Pharmaceuticals is owned by 0.06% institutional investors, 28.48% insiders, and 71.46% retail investors. Algert global is the largest institutional shareholder, holding 0% of DCPH shares. UBS: US Equity Small Cap Growth is the top mutual fund, with 1.12% of its assets in Deciphera Pharmaceuticals shares.
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Algert global | - | - | - |
Price t rowe associates inc /md/ | - | - | - |
Geode capital management | - | - | - |
Voya investment management | - | - | - |
Fisher asset management | - | - | - |
Proshare advisors | - | - | - |
Dana investment advisors | - | - | - |
Jupiter asset management | - | - | - |
Sunesis advisors | - | - | - |
Intrust bank na | - | - | - |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Algert global | - | - | - |
Price t rowe associates inc /md/ | - | - | - |
Geode capital management | - | - | - |
Voya investment management | - | - | - |
Fisher asset management | - | - | - |
Proshare advisors | - | - | - |
Dana investment advisors | - | - | - |
Jupiter asset management | - | - | - |
Sunesis advisors | - | - | - |
Intrust bank na | - | - | - |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Rothschild investment | - | - | -10.00 |
First horizon advisors | - | - | -30.00 |
Parallel advisors | - | - | -62.00 |
Farther finance advisors | - | - | -74.00 |
Cwm | - | - | -83.00 |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Blackrock | - | - | -5.99M |
Armistice capital | - | - | -5.90M |
Redmile group | - | - | -5.30M |
Deerfield management company, l.p. (series c) | - | - | -5.13M |
Vanguard group | - | - | -4.57M |
Sold Out
Holder | Change |
---|---|
Rothschild investment | -10.00 |
First horizon advisors | -30.00 |
Parallel advisors | -62.00 |
Farther finance advisors | -74.00 |
Cwm | -83.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2024 | 1 | -99.44% | 50,000 | -99.92% | - | 0.00% | - | -100.00% | - | -100.00% |
Mar 31, 2024 | 177 | 7.27% | 59,551,887 | 2.76% | 70 | 1.51% | 93 | 1.09% | 53 | 10.42% |
Dec 31, 2023 | 165 | 3.77% | 57,953,451 | 2.41% | 68 | 1.54% | 92 | 22.67% | 48 | -12.73% |
Sep 30, 2023 | 159 | 8.16% | 56,588,465 | 0.67% | 66 | 1.44% | 75 | 8.70% | 55 | 27.91% |
Jun 30, 2023 | 147 | -2.65% | 56,212,961 | -3.13% | 67 | 1.38% | 69 | -16.87% | 43 | - |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
UBS: US Equity Small Cap Growth | 968.92K | 1.12% | - |
Man GLG Event Driven Alternative IN USD | 552.28K | 0.64% | 136.57K |
MEDICAL BioHealth EUR Acc | 391.10K | 0.45% | - |
Arbitrage R | 379.98K | 0.44% | 379.98K |
Empower Small Cap Growth/Emerald SP | 148.39K | 0.17% | - |
Goldman Sachs Small Cp Val Insghts Instl | 103.83K | 0.12% | - |
NT R2000 Value Index Fund - NL | 100.24K | 0.12% | -425.00 |
AltShares Merger Arbitrage ETF | 88.93K | 0.10% | 88.93K |
Jupiter Merian Glb Eq AbsRet I USD Acc | 87.54K | 0.10% | 25.38K |
Water Island Event-Driven Fund I | 60.51K | 0.07% | 60.51K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Feb 16, 2024 | Sherman Matthew L | EVP & Chief Medical Officer | Sell | $40.84K |
Feb 16, 2024 | Kelly Thomas Patrick | Chief Financial Officer | Sell | $47.01K |
Feb 16, 2024 | Pitman Jama | SVP, Chief Development Officer | Sell | $35.41K |
Feb 16, 2024 | Martin Daniel C. | Chief Commercial Officer | Sell | $35.41K |
Jan 16, 2024 | Sherman Matthew L | EVP & Chief Medical Officer | Sell | $35.23K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q2 | - | - |
2024 Q1 | - | 8 |
2023 Q4 | - | 12 |
2023 Q3 | - | - |
2023 Q2 | 2 | 5 |
DCPH Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools